Innovative Trial Results from the B-Series OCT with ImgAssist AI
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) has made significant strides in breast cancer surgery technology with the release of impactful results from its pivotal trial focusing on their B-Series OCT with ImgAssist AI 2.0. This pioneering intraoperative margin assessment technology is designed to enhance surgical precision during breast-conserving surgeries, leading to improved patient outcomes.
Trial Highlights and Primary Findings
The pivotal trial achieved remarkable success, presenting data that indicates a substantial reduction in the number of patients with residual cancer during surgery, achieving a p-value of 0.0050. This statistic highlights the potential of the Perimeter B-Series to outperform standard care methods. Key data from this study were shared at the American Society of Breast Surgeons Annual Meeting, underscoring new analyses, including secondary endpoints and noteworthy reporting efforts.
Dr. Alastair Thompson, the trial's principal investigator and a distinguished surgeon, emphasized the need for enhanced intraoperative margin assessments. He stated that the trial's outcomes pave the way for improved decision-making, allowing surgeons to effectively identify areas of concern during surgery, ultimately reducing the necessity for re-excisions associated with leftover cancerous tissues.
Comprehensive Analysis of Trial Data
The analysis involved 206 breast cancer patients undergoing breast-conserving surgery. Notably, 35 out of these patients had residual diseased margins post-standard care. However, the introduction of the Perimeter B-Series identified residual disease in 14 additional patients. This meant that 20% of these patients were ultimately cleared of all residual cancer, thus meeting the predefined goals for trial performance.
Clinical Benefits Observed
The clinical benefits of using the Perimeter B-Series were evident, with 26 patients showing favorable outcomes due to enhanced detection of residual cancers. This included six individuals who had undetected disease that went unaddressed during prior standard procedures.
CEO Insights and Company Vision
Adrian Mendes, the CEO of Perimeter Medical Imaging AI, shared insights on the company’s vision to transform breast cancer surgeries. He expressed the firm belief that the Perimeter B-Series will significantly aid surgeons in managing cancer margins more effectively, minimizing the removal of healthy tissue. This advancement is aimed at reducing the anxiety that patients experience while waiting for post-operative pathology results.
Making Regulatory Progress
Moreover, in an important regulatory milestone, Perimeter announced the submission of a Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA). This submission, which incorporates the results of the pivotal trial, represents an essential step towards achieving necessary regulatory approvals for their cutting-edge technology in the United States marketplace.
About Perimeter Medical Imaging AI, Inc.
Perimeter Medical Imaging AI, a leader in medical technology, is committed to revolutionizing cancer surgeries with state-of-the-art imaging tools. With a strong presence in the U.S. market, the company has received clearance for its Perimeter S-Series OCT system, facilitating real-time visualization of excised tissues at the cellular level. Furthermore, the Perimeter B-Series OCT with ImgAssist AI is on track to set new benchmarks in intraoperative assessments.
With a grant totaling up to $7.4 million from the Cancer Prevention and Research Institute of Texas supporting their research, Perimeter thrives on innovation aimed at meeting high unmet medical needs in oncology.
Frequently Asked Questions
What is the primary purpose of the B-Series OCT with ImgAssist AI?
The B-Series aims to enhance intraoperative margin assessment during breast-conserving surgeries, reducing leftover cancerous tissue.
What were the results of the pivotal trial?
The trial showed a significant reduction in residual cancer during surgeries, indicating a successful detection of cancerous margins.
How does the Perimeter B-Series benefit patients?
This technology allows for more precise surgeries, which can result in fewer re-excisions and quicker recovery times for patients.
Where is Perimeter Medical Imaging AI based?
The company operates in both Toronto and Dallas, providing innovative solutions in medical imaging.
What is the significance of the PMA application to the FDA?
The PMA application is a crucial step towards regulatory approval for the Perimeter B-Series, potentially allowing its use in clinical settings across the U.S.
